Cemiplimab

立即咨询

Cemiplimab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1801342-60-8

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品介绍

Cemiplimab (Anti-Human PD-1) 是一种具有高亲和力的程序性死亡受体-1 (PD-1) 单克隆 IgG4 抗体，可阻断 PD-1/PD-L1 介导的 T 细胞抑制。常用于鳞状细胞皮肤癌研究。

生物活性

Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonalIgG4antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skincancerresearch^[1]^[2].

体内研究
(In Vivo)

Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model^[2].

Animal Model:	Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells^[2]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; five injections within 2 weeks
Result:	Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone. Significantly increased the proportion of CD4⁺TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.

Clinical Trial

CAS 号

1801342-60-8

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.